{"id":3849,"date":"2024-07-17T10:44:26","date_gmt":"2024-07-17T08:44:26","guid":{"rendered":"https:\/\/wordpress-famicord-ch.empressia.dev\/our-experience\/unsere-transplantationen"},"modified":"2025-11-25T16:42:14","modified_gmt":"2025-11-25T15:42:14","slug":"list-of-transplantations","status":"publish","type":"page","link":"https:\/\/famicord.lu\/en\/our-experience\/list-of-transplantations","title":{"rendered":"List of transplantations"},"content":{"rendered":"\n
\n\t
\n\t\t

\n\t\t\t\t\t\t\tList of<\/span>\n\t\t\t\n\t\t\t\t\t\t\t\n\t\t\t\n\t\t\t\t\t\t\ttransplantations<\/span>\n\t\t\t\t\t<\/h1>\n\t<\/div>\n\n\t
\n\t\t\n\t\t\t\n\t\t\t\t\n\t\t\t<\/mask>\n\t\t\t\n\t\t\t\t\n\t\t\t<\/g>\n\t\t\t\n\t\t<\/svg>\n\t<\/div>\n\n\t
\n\t\t\n\t\t\t\n\t\t\t\t\n\t\t\t<\/mask>\n\t\t\t\n\t\t\t\t\n\t\t\t<\/g>\n\t\t\t\n\t\t<\/svg>\n\t<\/div>\n<\/section>\n\n\n
\n
\n
\n \n

\n\n List of uses for stem cells approved by the FamiCord Group\u2019s laboratories:\n\n <\/h2>\n\n <\/header>\n <\/div>\n \n
\n
\n \n\t\n\t\t\n\t\t\t\n\t
\n\n\t\t\n\t\t\t\t\t\t\"Image\"\n\n\t\t\n\t<\/figure>\n\n\n\t\t\n\t\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
List of uses for stem cells approved by the FamiCord Group\u2019s laboratories:<\/caption>\n
Nr.<\/th>\n Source<\/th>\n Source type<\/th>\n Diagnosis<\/th>\n Medical sector<\/th>\n Year of application<\/th>\n Therapy<\/th>\n Country<\/th>\n Age of the recipient<\/th>\n <\/tr>\n <\/thead>\n
1<\/td>\n Skeletal Muscle<\/td>\n Allogeneic – Related<\/td>\n Duchenne Muscular Dystrophy (DMD)<\/td>\n Genetic Disorder<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 14<\/td>\n <\/tr>\n
2<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related <\/td>\n Autism<\/td>\n Neurology <\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Slovakia<\/td>\n 4<\/td>\n <\/tr>\n
3<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology <\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Slovakia<\/td>\n 4<\/td>\n <\/tr>\n
4<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Autism<\/td>\n Neurology <\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 7,11<\/td>\n <\/tr>\n
5<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Autism<\/td>\n Neurology <\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 5,3<\/td>\n <\/tr>\n
6<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Autism<\/td>\n Neurology <\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 7,11<\/td>\n <\/tr>\n
7<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral Palsy<\/td>\n Neurology <\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 3,11<\/td>\n <\/tr>\n
8<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cartilage Lesions<\/td>\n Orthopedics<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 67,2<\/td>\n <\/tr>\n
9<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cartilage Lesions<\/td>\n Orthopedics<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 50,7<\/td>\n <\/tr>\n
10<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 4,6<\/td>\n <\/tr>\n
11<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 6,5<\/td>\n <\/tr>\n
12<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 6,7<\/td>\n <\/tr>\n
13<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 6,5<\/td>\n <\/tr>\n
14<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n GvHD<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 2,9<\/td>\n <\/tr>\n
15<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 3,1<\/td>\n <\/tr>\n
16<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cartilage Lesions<\/td>\n Orthopedics<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 60,7<\/td>\n <\/tr>\n
17<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n GvHD<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 5,5<\/td>\n <\/tr>\n
18<\/td>\n Cord Tissue<\/td>\n Allogeneic<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n United Arab Emirates<\/td>\n 6<\/td>\n <\/tr>\n
19<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n GvHD<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 4,1<\/td>\n <\/tr>\n
20<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 4,9<\/td>\n <\/tr>\n
21<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 8,7<\/td>\n <\/tr>\n
22<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Cerebral palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 3,2<\/td>\n <\/tr>\n
23<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 2<\/td>\n <\/tr>\n
24<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related <\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 6<\/td>\n <\/tr>\n
25<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related <\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 13<\/td>\n <\/tr>\n
26<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related <\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 8<\/td>\n <\/tr>\n
27<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related <\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 9<\/td>\n <\/tr>\n
28<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 8<\/td>\n <\/tr>\n
29<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 5<\/td>\n <\/tr>\n
30<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 3<\/td>\n <\/tr>\n
31<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related <\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 3<\/td>\n <\/tr>\n
32<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Poland<\/td>\n 7,1<\/td>\n <\/tr>\n
33<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Optic Atrophy<\/td>\n Ophthalmology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Poland<\/td>\n 76,3<\/td>\n <\/tr>\n
34<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Encephalitis, Myelitis<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Poland<\/td>\n 36,6<\/td>\n <\/tr>\n
35<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Stress Incontinence<\/td>\n Urology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Poland<\/td>\n 62,4<\/td>\n <\/tr>\n
36<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n aGvHD, PNH<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Poland<\/td>\n 17,8<\/td>\n <\/tr>\n
37<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Progressive Bulbar Palsy<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 58,1<\/td>\n <\/tr>\n
38<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 6,2<\/td>\n <\/tr>\n
39<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Spinocerebellar Ataxia<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 59,4<\/td>\n <\/tr>\n
40<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n aGvHD<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 15,5<\/td>\n <\/tr>\n
41<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n aGvHD<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 12,1<\/td>\n <\/tr>\n
42<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n aGvHD<\/td>\n Hematology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 10<\/td>\n <\/tr>\n
43<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 4,6<\/td>\n <\/tr>\n
44<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 8,9<\/td>\n <\/tr>\n
45<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 5,2<\/td>\n <\/tr>\n
46<\/td>\n Cord Blood<\/td>\n Allogeneic – Unrelated<\/td>\n Acute Leukemia in remission, Pancytopenia after treatment<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Denmark<\/td>\n 18, 6<\/td>\n <\/tr>\n
47<\/td>\n Cord Blood<\/td>\n Allogeneic – Related<\/td>\n Juvenile Myelomonocytic Leukemia (JMML)<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 10, 10<\/td>\n <\/tr>\n
48<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 6,9<\/td>\n <\/tr>\n
49<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 7,2<\/td>\n <\/tr>\n
50<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 5,5<\/td>\n <\/tr>\n
51<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 4,1<\/td>\n <\/tr>\n
52<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 8,6<\/td>\n <\/tr>\n
53<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Slovakia<\/td>\n 7,6<\/td>\n <\/tr>\n
54<\/td>\n Cord Blood<\/td>\n Allogeneic<\/td>\n Thalassemia Major<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Turkey<\/td>\n 7,8<\/td>\n <\/tr>\n
55<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism <\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 8,9<\/td>\n <\/tr>\n
56<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Slovakia<\/td>\n 4,5<\/td>\n <\/tr>\n
57<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 3,5<\/td>\n <\/tr>\n
58<\/td>\n Cord Blood<\/td>\n Autologous <\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 8<\/td>\n <\/tr>\n
59<\/td>\n Cord Blood<\/td>\n Autologous <\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 5<\/td>\n <\/tr>\n
60<\/td>\n Cord Blood<\/td>\n Autologous <\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Slovakia<\/td>\n 3<\/td>\n <\/tr>\n
61<\/td>\n Cord Blood<\/td>\n Autologous <\/td>\n Autism<\/td>\n Neurology<\/td>\n 2026<\/td>\n Experimental Therapy <\/td>\n Poland<\/td>\n 6,5<\/td>\n <\/tr>\n
62<\/td>\n Cord Blood<\/td>\n Allogeneic – Related<\/td>\n Diamond-Blackfan Anemia (DBA)<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 10, 1<\/td>\n <\/tr>\n
63<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n T-Cell Lymphoma<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Netherlands<\/td>\n 65<\/td>\n <\/tr>\n
64<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Other Malignancy<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n France<\/td>\n 51<\/td>\n <\/tr>\n
65<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Italy<\/td>\n 27<\/td>\n <\/tr>\n
66<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n France<\/td>\n 14<\/td>\n <\/tr>\n
67<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n France<\/td>\n 68<\/td>\n <\/tr>\n
68<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n United Kingdom<\/td>\n 43<\/td>\n <\/tr>\n
69<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 68<\/td>\n <\/tr>\n
70<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 69<\/td>\n <\/tr>\n
71<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 67<\/td>\n <\/tr>\n
72<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 64<\/td>\n <\/tr>\n
73<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 73<\/td>\n <\/tr>\n
74<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n United Kingdom<\/td>\n 26<\/td>\n <\/tr>\n
75<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 74<\/td>\n <\/tr>\n
76<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Netherlands<\/td>\n 66<\/td>\n <\/tr>\n
77<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Romania<\/td>\n 25<\/td>\n <\/tr>\n
78<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Other Myelofibrosis\/Myelosclerosis<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 65<\/td>\n <\/tr>\n
79<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 62<\/td>\n <\/tr>\n
80<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 63<\/td>\n <\/tr>\n
81<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Netherlands<\/td>\n 47<\/td>\n <\/tr>\n
82<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Czechia<\/td>\n 67<\/td>\n <\/tr>\n
83<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Sweden<\/td>\n 74<\/td>\n <\/tr>\n
84<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Non-Hodgkin Lymphoma<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 72<\/td>\n <\/tr>\n
85<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Ukraine<\/td>\n 40<\/td>\n <\/tr>\n
86<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n No Data<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 70<\/td>\n <\/tr>\n
87<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Hungary<\/td>\n 35<\/td>\n <\/tr>\n
88<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n USA<\/td>\n 71<\/td>\n <\/tr>\n
89<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Primary Myelofibrosis<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 37<\/td>\n <\/tr>\n
90<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n France<\/td>\n 68<\/td>\n <\/tr>\n
91<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Fanconi Anemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 4<\/td>\n <\/tr>\n
92<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myeloid Leukemia (Relapse)<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 66<\/td>\n <\/tr>\n
93<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 70<\/td>\n <\/tr>\n
94<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n France<\/td>\n 42<\/td>\n <\/tr>\n
95<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Netherlands<\/td>\n 57<\/td>\n <\/tr>\n
96<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Polycythaemia Vera<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 61<\/td>\n <\/tr>\n
97<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n CMML – Beginning Relapse<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Netherlands<\/td>\n 63<\/td>\n <\/tr>\n
98<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Australia<\/td>\n 64<\/td>\n <\/tr>\n
99<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 76<\/td>\n <\/tr>\n
100<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2026<\/td>\n Standard Therapy<\/td>\n Switzerland<\/td>\n 66<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n